Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

Background Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few
effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–…

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number of …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …

The global nephrology community recognises the need for a cohesive plan to address the
problem of chronic kidney disease (CKD). In July, 2016, the International Society of …

Background Short-term treatment for people with type 2 diabetes using a low dose of the
selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing …

SGLT2 inhibitors and GLP-1 receptor agonists are used in patients with type 2 diabetes as
glucose lowering therapies, with additional benefits of weight loss and blood pressure …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors
reduce the risk of adverse kidney and cardiovascular outcomes in patients with heart …

An absolute, supraphysiologic elevation in GFR is observed early in the natural history in 10%–67%
and 6%–73% of patients with type 1 and type 2 diabetes, respectively. Moreover, at …